Figure 3 | Scientific Reports

Figure 3

From: Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

Figure 3

PFS2 (as determined by investigator assessment) in the olaparib and chemotherapy TPC arms in the Asian subgroup. Data cut-off 9 December 2016; PFS2 data maturity, 57% (50/87 patients). bid, twice daily; CI, confidence interval; HR, hazard ratio; PFS2, time to second progression or death; TPC, treatment of physician’s choice.

Back to article page